Cargando…
Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
INTRODUCTION: Erlotinib’s gastrointestinal solubility and absorption are decreased by proton pump inhibitors (PPIs). Since erlotinib is a lipophilic drug, we hypothesized that concomitant intake with the fatty beverage milk may be a feasible way to increase erlotinib uptake. We performed a two-perio...
Autores principales: | Veerman, G. D. Marijn, Hussaarts, Koen G. A. M., Peric, Robert, Oomen-de Hoop, Esther, Landa, Kersten D., van der Leest, Cor H., Broerse, Suzanna D., Rutten, Hugo B., Belderbos, Huub N. A., Steendam, Christi M. J., Paats, Marthe S., Koolen, Stijn L. W., Dingemans, Anne-Marie C., van Gelder, Teun, van Leeuwen, Roelof W. F., Aerts, Joachim G. J. V., Mathijssen, Ron H. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808986/ https://www.ncbi.nlm.nih.gov/pubmed/32557346 http://dx.doi.org/10.1007/s40262-020-00910-1 |
Ejemplares similares
-
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020) -
Improving the tolerability of osimertinib by identifying its toxic
limit
por: Agema, Bram C., et al.
Publicado: (2022) -
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019) -
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023) -
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
por: Veerman, G.D. Marijn, et al.
Publicado: (2023)